| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Yaqub F | T-DM1 for HER2-positive metastatic breast cancer. | 2013 | Lancet Oncol. | pmid:23580966 |
| Ballantyne A and Dhillon S | Trastuzumab emtansine: first global approval. | 2013 | Drugs | pmid:23620199 |
| Carrasco-Triguero M et al. | Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. | 2013 | Bioanalysis | pmid:23641693 |
| Dere R et al. | PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. | 2013 | Bioanalysis | pmid:23641694 |
| Sullivan AS et al. | Interaction of rhizoxin with bovine brain tubulin. | 1990 | Cancer Res. | pmid:2364385 |
| Ismaili N et al. | [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer]. | 2013 | Presse Med | pmid:23721860 |
| DeFrancesco L | Drug pipeline: 1Q13. | 2013 | Nat. Biotechnol. | pmid:23752422 |
| Johnson MS | The top 10 drug trends right now. | 2013 | Nurs Manage | pmid:23764906 |
| Pegram M | Treatment combinations for HER2-positive breast cancer. | 2013 | Oncology (Williston Park, N.Y.) | pmid:23781688 |
| Yamashita-Kashima Y et al. | Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. | 2013 | Oncol. Rep. | pmid:23783223 |
| Wood AC et al. | Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. | 2013 | Pediatr Blood Cancer | pmid:23798344 |
| Kuo YH et al. | Antitumor agents, 112. Emarginatine B, a novel potent cytotoxic sesquiterpene pyridine alkaloid from Maytenus emarginata. | 1990 Mar-Apr | J. Nat. Prod. | pmid:2380715 |
| Gradishar WJ | Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. | 2013 | Ann. Oncol. | pmid:23827380 |
| Pan W et al. | Asm8, a specific LAL-type activator of 3-amino-5-hydroxybenzoate biosynthesis in ansamitocin production. | 2013 | Sci China Life Sci | pmid:23832249 |
| Bighin C et al. | Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. | 2013 | Future Oncol | pmid:23837759 |
| Diéras V and Bachelot T | The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. | 2014 | Target Oncol | pmid:23852665 |
| Haddish-Berhane N et al. | On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. | 2013 | J Pharmacokinet Pharmacodyn | pmid:23933716 |
| Sapra P et al. | Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. | 2013 | Expert Rev Clin Pharmacol | pmid:23978126 |
| Mancuso L et al. | Bioreduction of aryl azides during mutasynthesis of new ansamitocins. | 2013 | Org. Lett. | pmid:23981134 |
| Deckert J et al. | A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. | 2013 | Blood | pmid:24002446 |